CelluComp Ltd Competitors

Each year, millions of people hear the words no one wants to hear: "You have cancer." And behind each diagnosis lies a unique story, a family that deserves hope, a future that's worth fighting for. We know that no two treatment journeys are the same and delivering care is far from simple. It's complex, urgent, and deeply human. That’s why we don’t back down from challenges—we rise to them. From the smallest tumor change to the toughest clinical decisions, we see every obstacle as an opportunity to progress. That is what drives us. The people undergoing treatment. The clinicians providing the care. We are united in purpose. Together, we can create a world where every patient has access to the highest standard of care. This is our commitment because for everyone, it's personal. We are leading the innovation in personalized radiation therapy solutions. We are Elekta. Elekta reserves the right to remove any comment and to restrict access to its page at its sole discretion, without prior notice. The presence of user comments does not imply endorsement by Elekta, and Elekta makes no representations regarding the accuracy of such comments. User-generated content does not necessarily reflect the views, values, or positions of Elekta.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Founded in 1993, Alcimed is an Innovation and New Business consulting firm specialized in sectors driven by innovation : life sciences (biotech, healthcare, food), energy, environment, chemicals, cosmetics, materials, building, transportation, aeronautics, space and defence. Our purpose is to help both private and public decision-makers exploring and developing their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate. Alcimed's clients are : - Industrial leaders - Start-ups and SMEs - Private Equity players and Public institutions. Our team is made up of 200 highly-qualified, multicultural and passionate individuals with a dual culture in science/technology and business. We have 7 offices in 5 countries : France, Germany, Italy, Singapore and the USA. Want to know more? https://www.alcimed.com